The study of ICP-723 in patients with advanced solid tumors
InnoCare Pharma Inc is starting a new clinical trial of Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors.
During this study, dose escalation will be conducted in subjects with advanced solid tumors who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, tolerability, and PK of ICP-723
The clinical trial started on July 30, 2021 and will continue throughout July 2024.
Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity.
Among the main inclusion criteria are the following: patients with histopathologically confirmed locally advanced malignant solid tumors that are unresectable or metastatic and that are unresponsive to standard treatments or have relapsed; patients who have progressed under standard treatment including prior treatment with TRK or ROS1 inhibitors; patients ≥18 and ≤80 years old with measurable lesion according to RECIST and with adequate organ functions that meet protocol requirement criteria.
The complete list of the inclusion and exclusion criteria, as well as contacts, and location can be found here:
